Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022


Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2022 after the market close on Wednesday, November 9 and will also host a conference call and webcast at 4:30 pm Eastern Standard Time on November 9, 2022.

Wednesday, November 9, 2022 @ 4:30 pm EST
Domestic: 1-888-204-4368
International: 1-323-994-2093
Conference ID: 2581187
Webcast: Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARRtm mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation. In addition, please connect with us on Twitter and LinkedIn. For more information visit www.ArcturusRx.com.


These press releases may also interest you

at 15:00
Kaiser Permanente has announced that Angela Dowling is the new regional president for Kaiser Permanente in Washington, effective February 13, 2023. In this role, she will lead the organization's focus on providing integrated, high-quality health care...

at 15:00
Ziegler, a specialty investment bank, is pleased to announce the successful closing of the Bishop Gadsden Episcopal Retirement Community (Bishop Gadsden) $29,200,000 Series 2023A and 2023B Bonds (collectively, the Series...

at 14:44
Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in cannabidiol ("CBD") hemp extract wellness products issues the following statement regarding the FDA's January 26th press announcement:...

at 14:30
The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.   The dysregulation of STAT3 has been implicated in several malignancies which have brought it into the spotlight for...

at 14:10
The "Global Genetic Toxicology Testing Market Size, Share & Industry Trends Analysis Report by Product, Type, Application (Pharmaceutical & Biotechnology, Food Industry, Cosmetics Industry), Regional Outlook and Forecast, 2022-2028" report has been...

at 14:07
[email protected], the oncology unit of Eli Lilly and Company , today announced that the U.S....



News published on 26 october 2022 at 16:35 and distributed by: